Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and $5 billion. It targets a protein found in the lining of the stomach that's expressed in some gastric cancers.
Astra has pegged potential annual sales for the treatment, whose full name is sonesitatug vedotin, at between $3 billion and $5 billion. It targets a protein found in the lining of the stomach that's expressed in some gastric cancers.
<iframe src="https://hindustansphere.com/embed/cluster/f825d12ac6d35aca3bd98735d60f109617bfab1c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Late-Stage Trial"></iframe>
